Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma
ChiCTR1800018915Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Bengbu Medical University
- Start
- Dec 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of latanoprost in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by First Affiliated Hospital of Bengbu Medical University. Primary endpoint: Objective response rate. Planned start Dec 2018; status: not yet recruiting.
02
Drugs
latanoprost
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR1800018915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018915.